The story of Viagra, and its developer copyright, presents a complex case study for investors. Initially a blockbuster drug, generating billions in revenue , its patent expiration created a deluge of generic competition , significantly eroding its dominance. While some businesses may seek to capitalize on related treatments , the present landscape